Annovis Bio Inc SEC Filings

Annovis Bio (ANVS) filed its Q3 2025 10‑Q reporting continued operating losses and a going‑concern warning. The company posted a Q3 net loss of $7.3 million as research and development rose to $6.3 million with spending tied to its 6‑month Alzheimer’s trial and a Parkinson’s open‑label extension. General and administrative costs fell to $1.1 million. Cash and cash equivalents were $15.3 million, and warrant liability measured at fair value was $299,000.

Year‑to‑date, the net loss was $19.0 million, with higher interest income reflecting cash raised earlier in the year. Management concluded that existing cash is not sufficient for the period through one year after this report, indicating substantial doubt about the company’s ability to continue as a going concern, and plans to seek additional capital.

Financing activity included a February 2025 underwritten offering of 5.3 million units at $4.00 per unit (net proceeds $19.3 million) and sales under an ATM program. Subsequent to quarter‑end, the company raised $5.5 million in a registered direct offering on October 10, 2025 and $3.1 million on October 26, 2025. Shares outstanding were 20,187,904 at September 30, 2025; as of November 12, 2025, outstanding shares were 26,502,889.

Annovis Bio (ANVS) reported an insider share purchase by President & CEO and Director Maria Maccecchini. On 10/28/2025, she acquired 97,561 shares of common stock at $2.05 per share.

Following the transaction, she beneficially owns 1,212,020 shares, held directly. This filing reflects a personal share acquisition by a senior executive.

Annovis Bio (ANVS) — insider transaction. A director reported purchasing 975,610 shares of common stock at $2.05 on 10/28/2025 (Transaction Code P). Following the trade, the filer reported 2,455,539 shares held directly and 223,357 shares held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The filing notes the reporting person has voting and investment power over the trust-held shares.

Annovis Bio (ANVS) reported an insider transaction on a Form 4. Director Claudine Bruck exercised a stock option and acquired 7,142 shares of common stock at $0.14 per share on 09/10/2025 (transaction code M).

Following the transaction, her directly held common stock totaled 13,709 shares. The option exercised had been exercisable since 09/18/2016 and carried an expiration date of 09/18/2025, and the derivative position reported after the exercise was 0.

Annovis Bio entered into a registered direct offering and director subscriptions to issue an aggregate of 1,670,732 common shares at $2.05 per share. The company expects gross proceeds of approximately $3.425 million, before expenses. Of the total, 597,561 shares are being sold to purchasers under a Securities Purchase Agreement, and 1,073,171 shares are being purchased by two board members via Stock Subscription Agreements.

The closing is expected on or about October 28, 2025. Annovis plans to use net proceeds to continue clinical development of Buntanetap in a Phase 3 study for Alzheimer’s disease, and for working capital and general corporate purposes. The company agreed to issuance restrictions: no new securities without purchaser consent until November 28, 2025, and no Variable Rate Transactions until October 14, 2026, subject to exceptions.

A placement agent will receive a 7.0% cash fee on gross proceeds excluding shares sold to directors and executive officers. The placement agent will also receive immediately exercisable warrants to purchase up to 83,537 shares, with a five-year term and a $2.5625 exercise price; these warrants and underlying shares are registered under the same prospectus supplement.

Annovis Bio (ANVS) launched a registered direct primary offering of 1,670,732 shares of common stock at $2.05 per share, with gross proceeds of $3,425,001. The company estimates net proceeds of approximately $3.3 million, and the fee table shows proceeds to the company of $3,339,251 before expenses and fees. Annovis is also issuing placement agent warrants to purchase up to 83,537 shares at an exercise price of $2.5625 per share, exercisable for five years, and this supplement covers the common stock issuable upon their exercise.

H.C. Wainwright & Co. acted as exclusive placement agent. A 7.0% cash fee applies only to 597,561 shares, totaling $85,750. Shares outstanding were 24,443,938 as of October 24, 2025, and are expected to be 26,114,670 after the offering. Annovis plans to use proceeds to advance a Phase 3 study of Buntanetap in Alzheimer’s disease and for working capital and general corporate purposes.

Annovis Bio (ANVS) announced a registered direct offering, agreeing to sell 3,150,000 shares of common stock at $1.50 per share and pre-funded warrants to purchase up to 850,000 shares at $1.4999 (with a $0.0001 exercise price). The company expects gross proceeds of approximately $6.0 million, before fees and expenses. The transaction is expected to close on or about October 14, 2025, after customary conditions.

The company plans to use net proceeds to continue clinical development of its lead compound Buntanetap in a Phase 3 Alzheimer’s study and for working capital and general corporate purposes. Annovis agreed for one year not to enter into Variable Rate Transactions, subject to exceptions, and obtained 45‑day lock-ups from directors and officers. The placement agent will receive a 7% cash fee, up to $50,000 for counsel plus $10,000 clearing expenses, and warrants to purchase 200,000 shares at $2.20, exercisable immediately for five years. The securities are offered under an effective Form S-3 and a prospectus supplement dated October 10, 2025.

Annovis Bio (ANVS) launched a registered direct offering of 3,150,000 shares of common stock at $1.50 per share and pre-funded warrants to purchase up to 850,000 shares at $1.4999, each pre-funded warrant carrying a $0.0001 exercise price. The company is also registering placement agent warrants to purchase up to 200,000 shares at $2.20.

Gross proceeds are listed at $5,999,915 with a 7.0% placement fee; estimated net proceeds are approximately $5,515,000, to fund a Phase 3 Alzheimer’s study of Buntanetap and for working capital. The pre-funded warrants are immediately exercisable and include a beneficial ownership cap of 4.99%, or 9.99% at the purchaser’s election. Shares outstanding would be 24,152,377 after the offering, assuming full exercise of pre-funded warrants and no exercise of placement agent warrants, based on 20,152,377 shares as of October 10, 2025.

H.C. Wainwright & Co. served as exclusive placement agent. Annovis notes prior clinical results in Parkinson’s and Alzheimer’s studies and alignment with the FDA on an AD Phase 3 program while highlighting ongoing capital needs.